Markers will form the basis of a DNA diagnostic test to identify women who may benefit from more intensive screening; latest findings folded into
REYKJAVIK, Iceland, April 27 /PRNewswire-FirstCall/ -- Scientists from deCODE genetics (Nasdaq: DCGN) today report the discovery of two common single-letter variants (SNPs) on chromosome 5 of the human genome that are associated with risk of estrogen receptor-positive (ER+) breast cancer. More than 60% of the general population carry at least one copy of the risk variant of the most important SNP, called rs4415084, and women who have inherited the variant from both parents are at approximately 50% greater risk of developing ER+ breast cancer than women who have not inherited the variant. The second variant is located nearby and occurs only in tandem with the first, adding slight risk of the disease. Although these variants confer modest risk, they are so common that they are estimated to account for approximately 11% of breast cancers overall. The paper, 'Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer,' is published today in the online edition of Nature genetics, at http://www.nature.com/ng.
With this latest discovery, the genetic factors underpinning a very significant proportion of inherited risk of ER+ breast cancer have now been elucidated. Common variants previously discovered by deCODE on chromosomes 2q35 and 16q12 are together involved in an estimated 25% of ER+ breast cancers. The analysis in today's paper also reveals that a fourth known set of variants, located on chromosome 10q26 and accounting for approximately 16% of breast cancers, appear to confer risk exclusively of ER+ tumors. deCODE is applying these variants as the basis for a DNA-based reference laboratory risk-assessment test the company plans to launch in the coming months. Such a test will allow for the identification of women who may benefit from regular screening with standard as well as new, high-resolution technologies. The American Cancer Society now recommends that women who are at a 20-50% above- average risk of breast cancer should consider undergoing annual magnetic- resonance imaging (MRI) scans as well as mammograms.
"Within the past two years we have identified specific sequence variants that underlie much of the inherited risk of the common forms of breast cancer, the most frequently diagnosed cancer in women. And we have now reached a long awaited tipping point in this progress: the ability to identify, through a simple genetic test, a large proportion of women who are at a clinically- meaningful risk of the disease. The rationale for such testing is all the more compelling in ER+ cancers, since drugs such as tamoxifen have been shown to be successful in preventing as well as treating these cancers, and other drugs now in development may prove to be safe as long-term prophylactic therapy as well. deCODE's pioneering work in this field has also demonstrated that ER+ and ER- breast cancer appear to have distinct genetic bases, a phenomenon which may open the way to a better understanding of the nature, treatment and prevention of breast cancer in general. One of the most pressing next steps in this research is to analyze these results in large cohorts of women of non- European descent," said Kari Stefansson, CEO of deCODE.
deCODE made today's discovery through the analysis of genotypic data from a total of nearly 40,000 patients and control subjects from five countries. The deCODE team analyzed both genome-wide data on some 300,000 SNPs, supplemented by data on a much smaller number of SNPs on chromosome 5p12.
deCODE gratefully acknowledges the participation of the patients and researchers who took part in this study.
About Breast Cancer
Breast cancer is the most common cancer and the second leading cause of cancer deaths among women. Breast cancers are classified as ER+ or ER- according to whether tumors are found to contain estrogen receptors; in women of European descent approximately three-quarters are ER+, and in women of African descent approximately 50% are ER+. An estimated 178,000 cases are diagnosed in the US every year and over 40,000 deaths will result from breast cancer. Though a substantial portion of risk of this common disease is clearly familial, it has taken painstaking research to find genetic variants predisposing to its common forms. The strongly predisposing mutations in the BRCA1 and BRCA2 genes have a less than 0.5% frequency in the general population in the US and Europe. These mutations are estimated to account for only 1-3% of all breast cancer cases. There is evidence that a substantial portion of the uncharacterized risk for breast cancer is genetic, and this has encouraged the search for additional breast cancer predisposition genes.
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. Through its CLIA-certified laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; and deCODE PrCa(TM) for prostate cancer. deCODE is delivering on the promise of the new genetics.(SM) Visit us on the web at http://www.decode.com; on our diagnostics website at http://www.decodediagnostics.com; and, for our pioneering personal genome analysis service, at http://www.decodeme.com.
Any statements contained in this presentation that relate to future
plans, events or performance are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results, and the timing of events, to
differ materially from those described in the forward-looking statements.
These risks and uncertainties include, among others, those relating to our
ability to obtain financing and to form collaborative relationships,
uncertainty regarding potential future deterioration in the market for
auction rate securities which could result in additional permanent
impairment charges, our ability to develop and market diagnostic products,
the level of third party reimbursement for our products, risks related to
preclinical and clinical development of pharmaceutical products, including
the identification of compounds and the completion of clinical trials, the
effect of government regulation and the regulatory approval processes,
market acceptance, our ability to obtain and protect intellectual property
rights for our products, dependence on collaborative relationships, the
effect of competitive products, industry trends and other risks identified
in deCODE's filings with the Securities and Exchange Commission, including,
without limitation, the risk factors identified in our most recent Annual
Report on Form 10-K and any updates to those risk factors filed from time
to time in our Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. deCODE undertakes no obligation to update or alter these
forward-looking statements as a result of new information, future events or
Edward Farmer Gisli Arnason Joy Bessenger
+1 212 343 2819 +354 570 1825 +1 212 481 3891
|SOURCE deCODE genetics|
Copyright©2008 PR Newswire.
All rights reserved